NeurotechMagProGet access
News & Press

MintNeuro and Motif Neurotech announce partnership and multi-year supply deal for miniature psychiatric BCI chips

PR Newswire4/30/2026ยท04/30/26๐Ÿ‡ช๐Ÿ‡บ Europe

Summary

London-based MintNeuro and Houston-based Motif Neurotech announced a formal partnership and multi-year commercial supply agreement on April 30, 2026 to accelerate the clinical availability of therapeutic BCIs for mental health. MintNeuro's ultra-low-power, compact neural interface chips โ€” already validated in Motif's pre-clinical work โ€” will be integrated into Motif's XCS wirelessly-powered brain implant for treatment-resistant depression. The partnership follows Motif receiving FDA Breakthrough Device Designation for XCS and FDA IDE approval for the RESONATE clinical trial. The collaboration includes aligning successive MintNeuro chip generations with Motif's clinical development roadmap.

Why it matters

The agreement runs across Motif's development path, from pre-clinical work through early clinical and pivotal studies, tying a chip supplier to a device developer's whole roadmap instead of leaving it a one-off collaboration. For MintNeuro it is an early commercial customer; for Motif it secures purpose-built, low-power sensing and stimulation chips as its implant moves into a clinical feasibility study.

#BCI#Neural Interfaces#Depression#Mental Health Tech#Industry#UK

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items โ€” updated daily.

Start free trial
Already a member? Sign in